Celtic Pharmaceutical Holdings L.P.

Overview

Celtic Pharmaceutical Holdings L.P. is a global private equity firm specializing in the biotechnology and pharmaceutical industries. Founded by Stephen Evans-Freke and John Mayo, CBE, the firm is headquartered in Bermuda, with offices in New York and London. Celtic Pharma focuses on acquiring and investing in late-stage pharmaceutical programs, managing their development through to regulatory approval. The firm's mission is to bridge the gap between the established pharmaceutical companies' new product pipeline challenges and the biotech industry's capital constraints. The firm's investment strategy centers on identifying and acquiring promising therapeutic products that have achieved proof of principle in human clinical studies. Celtic Pharma's in-house team of senior pharmaceutical development executives establishes the clinical, manufacturing, regulatory, and commercial strategies for the development of its products and oversees their execution. Upon achieving value-enhancing milestones, including completing Phase III pivotal studies, the firm partners with major pharmaceutical companies for continued development and commercialization. Celtic Pharma's portfolio includes investments in various therapeutic areas, such as oncology and ophthalmology. For instance, the firm has been involved in the development of Xerecept®, a synthetic version of the natural peptide hormone Corticotrophin Releasing Factor, for the treatment of edema associated with cerebral tumors. Additionally, Celtic Pharma has engaged in collaborations with companies like Resolvyx Pharmaceuticals to advance treatments for ophthalmic conditions. These initiatives reflect the firm's commitment to advancing innovative therapies in the pharmaceutical sector.

Portfolio Companies